UK News Pioneering drug that hits prostate cancer's weak spot

© Provided by Daily Mail MailOnline logo

Men with incurable prostate cancer have been offered hope of a longer life thanks to a drug that targets the disease's 'Achilles heel'.

Olaparib works by interfering with a key process that allows some tumour cells to repair themselves, and proved so effective in trials it's now being assessed for NHS use.

The drug is already given to women with a specific type of breast and ovarian cancer caused by the faulty BRCA gene, and prostate cancer experts have welcomed its 'profound' effect on a rapidly fatal form of the disease.

Roughly 50,000 men in the UK each year are diagnosed with cancer of the prostate – a gland found just below the bladder. Eight in ten survive a decade or more.

The new made-to-measure cancer therapy

A new method helps to find the right drug at the right time with the right dose. © Getty Images / FatCamera / istockphoto.com / futurezone Diagnosis: cancer. A hard blow for everyone affected. According to Statistics Austria, around 40,000 people are confronted with this finding every year in Austria - men somewhat more frequently than women. Today, however, the diagnosis often no longer means a death sentence.

High PSA levels are suggestive of prostate cancer onset, the public has long been told. Men who fall into this category are often encouraged to get biopsied and undergo The problem is that a biopsy or the prostate “removal” operation can cause a dormant cancer to spread through the rest of the body.

Prostate cancer commonly affects men. Learn about the stages of prostate cancer , what the PSA test detects, and the role it plays in staging. Some conditions related to the prostate can cause the gland to produce more PSA than normal. These include prostatitis, benign prostatic hyperplasia (enlarged

For those with early-stage prostate cancer – before it has started to spread – surgery alone is likely to provide a cure.

Even for those at later stages, when a cure is no longer possible, medicines that target the hormone testosterone, which drives many prostate cancers, are effective in controlling the disease for many years.

© Provided by Daily Mail Men with incurable prostate cancer have been offered hope of a longer life thanks to a drug that targets the disease's 'Achilles heel'. Pictured: How the drug would work

However, in some patients these drugs don't work. Chemotherapy can slow tumour growth, but these patients face a bleak prognosis.

Olaparib is highly effective in men with hormone-resistant prostate cancer, as long as they also carry the BRCA genetic fault, or other genetic faults – a group that accounts for roughly one in ten of all prostate cancer patients.

Hollyoaks: James tries to rescue Juliet

Can he get her out of the drug dealing ring?E4 airdate: Wednesday 02 December at 19:00

Androgens stimulate prostate cancer cells to grow. The main androgens in the body are testosterone and dihydrotestosterone (DHT). Most androgen is made by the testicles, but the adrenal glands (glands that sit above your kidneys) as well as the prostate cancer itself, can also make a fair amount.

Prostate cancer treatment can include active surveillance, surgery, radiation therapy, hormonal therapy, chemotherapy, immunotherapy, and supportive care. Learn more about treatment options for prostate cancer in this expert-reviewed summary.

Olaparib blocks the activity of an enzyme called PARP, which is produced by the body and helps repair damaged genetic material inside cells.

As part of the body's natural growth and repair process, cells replicate and divide. But when this happens, the genetic material inside them can develop faults. PARP is involved in repairing these errors when they occur.

Harry Styles among host of celebrities selling off items for cancer charity

Stars from entertainment and sport have contributed signed pieces of clothing for the Cahonas Scotland Celebrity Loosen Up Auction 2020. “It shows just how seriously everybody takes the need to raise awareness of testicular cancer.“Testicular cancer can have devastating effects for men and their families – but it doesn’t have to.

A new prostate cancer drug trial has been so successful doctors have decided to stop it early. Medics at London' s Royal Marsden Hospital were testing a powerful alpha 'It' s more damaging. It takes one, two three hits to kill a cancer cell compared with thousands of hits for beta particles,' he told the BBC.

Does testosterone increase your risk for prostate cancer ? We'll let you in on what the latest research says. Some researchers say that testosterone therapy may increase your risk for prostate cancer , but more research is needed to understand the link.

However, PARP, in particular, can also end up repairing genetic material inside some types of tumour cells too, helping drive cancers.

Olaparib attaches to PARP, blocking it from getting to the tumour cells' genetic material. This means they can't be repaired, and instead die.

Gallery: 20 things to know about prostate cancer (Espresso)

Importantly, because PARP isn't the only enzyme healthy cells rely on to repair faults, they keep functioning normally, limiting the collateral damage caused by the drug.

Not all cancers are driven by PARP, so patients must be tested to find out if they'll benefit from a drug like olaparib.

On average, men who can benefit from the drug live for three months longer. 'Some respond better than this,' explains oncologist Professor Hendrik-Tobias Arkenau, medical director of Sarah Cannon Research Institute UK.

'Prostate cancer often spreads to the bones, and on scans you'll see hundreds of tumours all over the body, like gunshots, in the shoulders, ribs, pelvis and spine, and legs. This causes severe pain, and risks fractures.

I'm A Celebrity stars share happiest moments of their lives as Victoria Derbyshire reflects on beating cancer

The stars of I'm A Celebrity gathered together to discuss some of the happiest moments of their lives.And the campmates have had some big discussions while on the show, some joyous and others poignant, and the deep meaningful conversations continued on Saturday night’s episode.

'Olaparib stops these tumours from growing. It helps with the pain and means patients are able to go about their lives.

The effect is profound. There are also fewer side effects, such as low mood and fatigue, than with hormone treatment.

© Provided by Daily Mail Roughly 50,000 men in the UK each year are diagnosed with cancer of the prostate ¿ a gland found just below the bladder. Eight in ten survive a decade or more. Pictured: Stock image

Patients can suffer digestive problems and may be prone to infections, but these can be managed.'

Olaparib is taken as twice-daily capsules, until the disease begins to progress, when patients would move to other treatments.

Sarah Harding insists she's 'fighting as hard as possible' amid 'tough' breast cancer battle

Girls Aloud star Sarah Harding has opened up on her ongoing battle with breast cancer, explaining she's being as brave as she knows how.The 39 year old, who announced last August the devastating news that she was diagnosed with advanced cancer, took to her Instagram feed to tell her 235,000 followers about an autobiography she's been working on during her treatment.

Professor Johann de Bono at the Institute of Cancer Research, who led the recent olaparib trial, said: 'Olaparib targets an Achilles heel in cancer cells, while sparing normal, healthy cells.

'I can't wait to see this drug start reaching men who could benefit from it on the NHS.'

One patient it helped is Peter Isard, 60, an investment consultant from London.

The married father-of-three was diagnosed with late-stage, incurable prostate cancer in January 2017 and was enrolled on the olaparib trial after he failed to respond to chemotherapy and hormone treatment.

His prostate cancer was linked to a mutation known as PALB2, which means he was likely to respond well to olaparib.

He said: 'Before I started the treatment, I wasn't expected to live more than two years, and had tumours all over my body.

'These have all gone, bar one which is much smaller. Other tests show I'm stable.'

Olaparib is now being assessed by NHS spending watchdog the National Institute for Health and Care Excellence (NICE) and could be offered to patients within months.

The official price for a month's supply is £3,950 – meaning an annual cost of roughly £50,000.

However, NICE would be expected to negotiate a significant discount.